Posted by Michael Wonder on 31 Mar 2025
Lilly’s statement about the CHMP opinion issued for donanemab
28 March 2025 - The EMA's CHMP issued an opinion that does not recommend Eli Lilly's donanemab be granted marketing authorisation for the treatment of early symptomatic Alzheimer's disease.
Lilly will seek re-examination by the CHMP.
